Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 6Etoposide 3Daunorubicin 3aldesleukin 2Vorinostat 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Idarubicin 2Clofarabine 2Busulfan 2Azacitidine 2valspodar 1tipifarnib 1fludarabine phosphate 1Topotecan 1Tacrolimus 1Pravastatin 1Mitoxantrone 1Gemtuzumab 1Cyclosporine 1Cyclophosphamide 1Calicheamicins 1Bortezomib 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Erythroblastic, Acute × Pravastatin × Clear all
NCT01342887 2017-07-02

Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
6 enrolled 6 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡